Zevra Therapeutics, Inc.
ZVRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434647
In the last 90 days, Zevra Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $642.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Zevra Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $613.2K in total
- Insiders trading
- 2
- Net value
- −$613.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Zevra Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Thompson Rahsaan | Chief Legal & Compliance | 37,569 | Aug 17, 2026 | 4 |
| Watton Corey Michael | Director | 1,800 | Aug 12, 2026 | 2 |
| Seymour Tamara A | Director | 3,894 | Jun 18, 2026 | 1 |
| Calder Douglas W | Director | – | Jun 18, 2026 | 1 |
| Secor Alicia | Director | – | Jun 18, 2026 | 2 |
| Shih Alvin | Director | 20,000 | Jun 18, 2026 | 1 |
| Anderson Thomas | Director | 20,000 | Jun 18, 2026 | 1 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | 29,590 | May 29, 2026 | 3 |
| Bode John B | Director | 123,400 | Mar 26, 2026 | 1 |
| Renz Justin A | CFO | – | Mar 19, 2026 | 1 |
| McFarlane Neil F. | President and CEO | 387,225 | Feb 10, 2026 | 3 |
| Schafer Joshua | CCO | 62,278 | Feb 4, 2026 | 2 |
| Quartel Adrian W | Chief Medical Officer | 9,723 | Feb 2, 2026 | 1 |
| Clifton R. LaDuane | Other: Former CFO & Treasurer | 143,515 | Jan 7, 2026 | 1 |
| Dixon Wendy L | Director | – | May 30, 2025 | 0 |
| Mickle Christal M M | Chief Development Officer | – | Feb 2, 2024 | 0 |
| Guenther Sven | Chief Scientific Officer | – | Feb 2, 2024 | 0 |
| Saluri Joseph | Director | – | May 8, 2023 | 0 |
| Plooster Matthew R | Director | 18,500 | May 8, 2023 | 0 |
| Tierney David S | Director | 10,835 | Mar 13, 2023 | 0 |
| Pascoe Richard W | Chief Executive Officer | 29,973 | Mar 13, 2023 | 0 |
| Mickle Travis C | President & CEO | 11,034Indirect | May 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 (view filing) | Feb 2 | Same day | McFarlane Neil F.President and CEO | SSale | −91.0K | $9.38 | −$853.6K | −20.0%364.4K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Sangiovanni Timothy J.SVP, Finance & Corp Controller | SSale | −1.75K | $8.82 | −$15.4K | −7.7%20.9K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Thompson RahsaanChief Legal & Compliance | SSale | −4.08K | $8.83 | −$36.0K | −7.6%49.9K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Quartel Adrian WChief Medical Officer | SSale | −4.53K | $8.83 | −$40.0K | −31.8%9.72K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Schafer JoshuaCCO | SSale | −3.38K | $8.83 | −$29.8K | −8.3%37.4K after | 10b5-1 |
| Feb 4, 2026 (view filing) | Feb 3 | 1 day | Sangiovanni Timothy J.SVP, Finance & Corp Controller | SSale | −3.00K | $9.18 | −$27.5K | −9.2%29.6K after | 10b5-1 |
| Feb 4, 2026 (view filing) | Feb 3 | 1 day | Schafer JoshuaCCO | SSale | −10.5K | $9.19 | −$96.5K | −14.4%62.3K after | 10b5-1 |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | McFarlane Neil F.President and CEO | SSale | −14.6K | $8.56 | −$125.2K | −3.6%387.2K after | 10b5-1 |
| May 13, 2026 (view filing) | May 11 | 2 days | Thompson RahsaanChief Legal & Compliance | SSale | −1.79K | $11.30 | −$20.3K | −3.6%48.1K after | 10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Thompson RahsaanChief Legal & Compliance | SSale | −34.6K | $12.68 | −$438.2K | −30.1%80.2K after | 10b5-1 |
| Aug 12, 2026 (view filing)4:16 PM ET | Aug 10 | 2 days | Watton Corey MichaelDirector | SSale | −12.3K | $11.25 | −$138.4K | −87.2%1.80K after | |
| Aug 17, 2026 (view filing)4:32 PM ET | Aug 14 | 3 days | Thompson RahsaanChief Legal & Compliance | SSale | −42.7K | $11.13 | −$474.8K | −53.2%37.6K after | 10b5-1 |